Bavarian Nordic updates phase III booster study plans, sets launch for August
The biotech firm aims to compare its Covid-19 vaccine candidate, ABNCoV2, with Pfizer/Biontech’s Comirnaty in a controlled, double-blind trial.
by christian bundgaard, translated by daniel pedersen
Bavarian Nordic has scheduled its phase III trial of its booster candidate against Covid-19, dubbed ABNCoV2, in August, according to a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna on booster race: May the best data win
For subscribers
.jpg&w=384&q=75)
